Chlorzoxazone is a centrally acting muscle relaxant drug administered in response to acute musculoskeletal syndrome. It is used as a relaxant against strains and sprain caused due to muscle pull, and is administered in combination with analgesics and physical therapy. White crystalline powder color and odorless tablet are the tangent features of the drug. Although chlorzoxazone is regarded as an ideal skeletal muscle relaxant available in the market, it has been seen to cause fatal liver diseases. Some other side effects of the drug include yellow eyes, abdominal bloating, dark skin texture, vomiting, diarrhea, and persistent nausea. Administration of the drug under pregnancy is of major concern due to possible negative reactions that might occur, and thus the drug should be taken only under prescription and proper guidance. The drug is available in various forms in tablets of 250 and 500mg. The brands for chlorzoxazone include Parafon Forte and Lorzone.
COVID-19 Impact Analysis
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the chlorzoxazone market.
Top Impacting Factors
- Rise in the number of spinal surgeries and an increase in geriatric population are expected to contribute to the growth of the chlorzoxazone market.
- Highly industrialized economies with their increasing obese population is witnessing an ever-increasing incidence of lower back pain and subsequent recommendations of skeletal muscle relaxants as the first line therapy. This, in turn, is expected to boost the demand for chlorzoxazone drug.
- However, increase in side effects such as fatal liver diseases and total respiratory arrests among others associated with administration of the drug is a possible growth restraint of the market.
- Lack of healthcare manufacturing infrastructure coupled with disrupted supply chains in underdeveloped nations is bound to hamper the market.
- Additionally, lack of awareness about the side effects of the drug in rural parts of India and emerging economies is a huge factor hampering the sales of the drug.
Key Market Trends
- Glenmark Pharma has recently been granted final permission by the U.S. Food and Drug Administration (FDA) for sale and administration of chlorzoxazone in the U.S. market.
- North America is anticipated to retain its position as the highest recipient of chlorzoxazone market, owing to rising number of populace suffering from skeletal disorders, presence of robust healthcare infrastructure, and availability of highly skilled professionals.
- Latin America and Middle East are potential markets for chlorzoxazone industry, owing to an increasing shift of population toward advanced therapeutic techniques.
- Another potential future market for the industry is Japan, owing to the entry of new drug manufacturers due to the presence of ageing population and the subsequent demand for advanced therapeutic techniques to prevent skin disorders.
- Higher number of COVID-19 cases in Asia-Pacific, including India, in past few months and the resulting side effects, including musculoskeletal sprains have led to increase in the manufacturing and distribution of chlorzoxazone to hospitals and pharmacy stores, which, in turn, has .augmented the market growth
Key Benefits of the Report
- This study presents the analytical depiction of the chlorzoxazone industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the market share.
- The current market is quantitatively analyzed to highlight the growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the Chlorzoxazone Report
- Which are the leading players active in the chlorzoxazone market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the chlorzoxazone market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What are the impacts of COVID-19 in the industry?
- What is chlorzoxazone?
- What is the chlorzoxazone market prediction in the future?
- What are the current trends and predicted trends?
Key Market Segments
- By Application
- Hospitals
- Retail Pharmacy
- Online Pharmacy
- By Product Type
- Type I
- Type II
- Type III
- Type IV
- By Region
- North America
- Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
Key Market Players
- Merck & Co. Inc.
- Novartis AG
- Intas Pharma Inc.
- MedPointe Pharmaceuticals
- Hoffman-La Roche Ltd
- Johnson & Johnson
- Meda Pharma Inc.
- Pfizer Inc
- Galderma S.A.
- Abbott Laboratories